Comparative Pharmacology
Head-to-head clinical analysis: CAPTOPRIL versus PRINIVIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPTOPRIL versus PRINIVIL.
CAPTOPRIL vs PRINIVIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion.
Lisinopril is an angiotensin-converting enzyme inhibitor that decreases angiotensin II production, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Initial: 25 mg PO 2-3 times daily; target dose: 50 mg PO 2-3 times daily; maximum: 450 mg/day. For heart failure: start 6.25-12.5 mg PO 3 times daily, titrate to 25-50 mg PO 3 times daily.
Initial dose 10 mg orally once daily; titrate to target dose of 20-40 mg daily based on blood pressure response.
None Documented
None Documented
Clinical Note
moderateCaptopril + Benzydamine
"The risk or severity of adverse effects can be increased when Captopril is combined with Benzydamine."
Clinical Note
moderateCaptopril + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Captopril."
Clinical Note
moderateCaptopril + Droxicam
"The risk or severity of adverse effects can be increased when Captopril is combined with Droxicam."
Clinical Note
moderateCaptopril + Loxoprofen
Terminal half-life 1.9 hours, prolonged to 3.5-32 hours in renal impairment; clinical context: requires adjusted dosing in renal failure
Terminal elimination half-life is approximately 12 hours, with accumulation noted in renal impairment; effective half-life at steady state extends to 30-50 hours in patients with creatinine clearance <30 mL/min.
Primarily renal (50-60% unchanged), with minor biliary/fecal elimination (<5%)
Renal excretion accounts for approximately 60% of total clearance, primarily as unchanged lisinopril; fecal excretion accounts for negligible amounts.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor
"The risk or severity of adverse effects can be increased when Captopril is combined with Loxoprofen."